Navigation Links
Arbitration Panel Finds in Favor of Tennessee Victim of Mariner Nursing Home Negligence
Date:9/3/2009

Unanimous Decision on Med Mal, Negligence, and TAPA Claims

HOUSTON, Sept. 3 /PRNewswire-USNewswire/ -- An arbitration panel found in favor of the estate of Mrs. Voncil Sherrod, who died on 3/24/05 from gangrene, which developed during her residency at High Pointe Health and Rehabilitation, a Mariner Health Care nursing home in Tennessee. Counsel for the Plaintiff at the arbitration trial were Kenneth Connor and Henry Giessel of the firm Marks, Balette & Giessel, P.C. and Matthew Mussalli.

The causes of action included claims for ordinary negligence, violation of the Tennessee Adult Protection Act (TAPA), and medical malpractice. Plaintiffs sought to recover compensatory and punitive damages, together with attorneys fees for violation of TAPA. Claims were asserted against Mariner Health Care, Inc. (the parent corporation), Mariner Health Care Management (the management company), and National Heritage Realty, Inc. (the licensee). Plaintiffs averred that the three companies operated the facility as a joint venture and that they served as the alter egos of one another.

"It is outrageous that Mrs. Sherrod was treated so horrifically. She wasn't turned and repositioned and developed terrible pressure ulcers. She wasn't kept clean and developed infections. In addition, she suffered the indignity of languishing in her own waste for long periods of time. We can only hope that other nursing homes take heed and reconsider the way in which they operate their facilities. It is particularly satisfying to have unanimous decisions when you seek justice for a negligence victim's family," said Kenneth Connor.

The arbitration panel, was comprised of two former trial and appellate judges and a lawyer who had represented Mariner. The parties each selected an arbitrator and those two arbitrators picked a third arbitrator who presided over the proceeding. The panel rendered its award, finding unanimously for the Plaintiff on the ordinary negligence, medical malpractice and TAPA survival claims. The damage awards (items X and XII in the link) were determined by a majority of the panel. A copy of the Arbitration Panel's findings is linked here: (http://www.marksfirm.com/pdf/media%20cover/TN_tapa_malpractice.pdf)

The amounts awarded, totaling $2,773,396.32 were as follows:

  • TAPA violations -- $250,000
  • Attorneys fees for intentional, malicious or fraudulent misconduct resulting in a TAPA violation -- $400,000
  • Medical malpractice -- $626,396.32
  • Punitive damages -- $1,500,000

Marks Balette & Giessel is a nationally recognized litigation firm focused on the trial of complex, high-stakes civil cases. The firm's unparalleled commitment, dedication to excellence, and passion for jury trials have resulted in some of the largest verdicts and settlements in the country. For more information about this firm and their results, please see their website at http://www.marksfirm.com/.


'/>"/>
SOURCE Marks Balette & Giessel
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. MDS Commences Arbitration against AECL over Cancelled MAPLE Project and Files $1.6 Billion Court Claim against AECL and the Government of Canada
2. Genesis Pharmaceuticals Successfully Defends Itself in a Multi-Million Dollar Arbitration, Two Other Arbitration Proceedings Against Genesis are Withdrawn
3. Genesis Successfully Defends Multi-Million Dollar Arbitration Filed by CRG and CRGP; Related Parties Withdraw Remaining Demands for Arbitration Against Genesis
4. Gen-Probe, Roche Prevail in Arbitration With Digene Concerning Human Papillomavirus Agreement
5. Johnson & Johnson Files Arbitration Demand Against Schering-Plough to Resolve Dispute Over Agreements for REMICADE(R) and SIMPONI(TM)
6. Bionovo Announces Arbitration Decision in Lawsuit Filed by Former Officer - All Claims Denied
7. Virginia Tech Review Panel Calls For Reform of Mental Health Treatment Law
8. CryoCor Invited to Participate in FDA Advisory Panel Meeting on Atrial Fibrillation
9. Patient Safety Authority Board of Directors Names Infection Advisory Panel
10. Partners Rx Chief Pharmacy Officer, Richard Bullard on Panel Discussion at the Fall 2007 Managed Markets Summit (MMS) in Phoenix, AZ.
11. Billians HealthDATA GM Speaking on Dreamforce 07 Panel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... Angeles, CA (PRWEB) , ... February 10, 2016 ... ... Programming (NLP) practitioner, is known locally for a series of therapeutic sessions to ... in-the-moment in their characters and in their lives. The series, known as “Mindfulness ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... unveiling its revolutionary new 2.0 version at the International Roofing Expo in Orlando, ... power of the world's most advanced weather technology in the hands of consumers, ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... master charity program created to assist the local community. Pledging to select a ... and nonprofit organizations in the area. Their goal is to bring community awareness ...
(Date:2/10/2016)... ... ... Ongoing news of the ravages of traumatic brain injury (TBI) among former ... takes a closer look at cases of TBI being managed by their members. The ... the aging population, and identifies the challenges associated with their care. , During the ...
(Date:2/10/2016)... ... February 10, 2016 , ... Armune BioScience signed a ... network of laboratory service centers across the country. Launched in April of 2015, Apifiny ... detection of prostate cancer. Apifiny order volume exceeded 3,000 tests in 2015. Primary care ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... -- Mast Therapeutics, Inc. (NYSE MKT: MSTX), ... cell disease and heart failure, today announced the pricing ... a price to the public of $0.275 per unit. ... common stock and one warrant to purchase one share ... of $0.42 per share. The warrants are exercisable six ...
(Date:2/10/2016)... Feb. 10, 2016  Silicon Biosystems Menarini Inc., ... that help uncover the biological complexities of disease ... a developer of innovative technologies for genomics research, ... aimed at enabling translational researchers to obtain high-quality ... hundred tumor and normal cells in an optimized ...
(Date:2/10/2016)... Feb. 9, 2016 CTI BioPharma Corp. ... an update regarding the clinical studies being conducted ... for pacritinib. Following the issuance of the Company,s ... clinical hold issued by the U.S. Food and ... Company received an oral communication from the FDA ...
Breaking Medicine Technology: